Pharma News, 2019

Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer in England.

(Reuters) - Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co’s immunotherapy...

Amsterdam, NL, February 14, 2019 - Despite challenges, new advances in stem cell biology and genetic engineering show potential for better cell replacement therapies, say experts in a special suppleme...

Cancer cells are, in some respects, impressive.

(Reuters) - Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug sh...

(Reuters) - Johnson & Johnson said on Wednesday it would buy Auris Health Inc for $3.

Pfizer executives say they're excited about Xtandi's prospects in HSPC.

The FDA has sent its first warning letter filed under the Drug Supply Chain Security Act to McKesson for allowing "illegitimate" drugs to get into the supply chain, FDA Commissioner Scott Go...

ISTANBUL (Reuters) - Turkey increased on Wednesday the fixed exchange rate by 26.

TEL AVIV/NEW YORK (Reuters) - Teva Pharmaceutical Industries is “content” with having its new migraine drug Ajovy covered by nearly two-thirds of payers in the United States, Chief Executi...

New York-based Progenics last year picked up an FDA approval for its orphan radiotherapeutic.

Gilead's CAR-T therapy Yescarta (axicabtagene ciloleucel) has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland.